IL101600A - Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them - Google Patents
Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing themInfo
- Publication number
- IL101600A IL101600A IL10160092A IL10160092A IL101600A IL 101600 A IL101600 A IL 101600A IL 10160092 A IL10160092 A IL 10160092A IL 10160092 A IL10160092 A IL 10160092A IL 101600 A IL101600 A IL 101600A
- Authority
- IL
- Israel
- Prior art keywords
- synthetic
- antisense oligodeoxynucleotides
- pct
- gene
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01007—Acetylcholinesterase (3.1.1.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01008—Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL10160092A IL101600A (en) | 1992-04-15 | 1992-04-15 | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
CA002118235A CA2118235C (en) | 1992-04-15 | 1993-04-15 | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
DE69308833T DE69308833T2 (de) | 1992-04-15 | 1993-04-15 | Synthetische "antisense" oligonucleoside und diese enthaltende arzneimittel |
JP5517984A JPH08504083A (ja) | 1992-04-15 | 1993-04-15 | 合成アンチセンスオリゴデオキシヌクレオチドとそれらを含む医薬組成物 |
US08/318,826 US5891725A (en) | 1992-04-15 | 1993-04-15 | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
AU40399/93A AU665087B2 (en) | 1992-04-15 | 1993-04-15 | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
AT93911467T ATE150029T1 (de) | 1992-04-15 | 1993-04-15 | Synthetische ''antisense'' oligonucleoside und diese enthaltende arzneimittel |
PCT/EP1993/000911 WO1993021202A1 (en) | 1992-04-15 | 1993-04-15 | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
EP93911467A EP0636137B1 (en) | 1992-04-15 | 1993-04-15 | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US08/850,347 US6110742A (en) | 1992-04-15 | 1997-05-02 | Synthetic antisense oligodeoxynucleotides targeted to AChE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL10160092A IL101600A (en) | 1992-04-15 | 1992-04-15 | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
Publications (2)
Publication Number | Publication Date |
---|---|
IL101600A0 IL101600A0 (en) | 1992-12-30 |
IL101600A true IL101600A (en) | 2000-02-29 |
Family
ID=11063549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10160092A IL101600A (en) | 1992-04-15 | 1992-04-15 | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
Country Status (9)
Country | Link |
---|---|
US (1) | US5891725A (xx) |
EP (1) | EP0636137B1 (xx) |
JP (1) | JPH08504083A (xx) |
AT (1) | ATE150029T1 (xx) |
AU (1) | AU665087B2 (xx) |
CA (1) | CA2118235C (xx) |
DE (1) | DE69308833T2 (xx) |
IL (1) | IL101600A (xx) |
WO (1) | WO1993021202A1 (xx) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2110946A1 (en) | 1992-12-09 | 1994-06-10 | Elazar Rabbani | Induction of immunocompatibility by nucleic acid |
GB9519299D0 (en) | 1995-09-21 | 1995-11-22 | Farrar Gwyneth J | Genetic strategy |
US8551970B2 (en) | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
GB9606961D0 (en) | 1996-04-02 | 1996-06-05 | Farrar Gwyneth J | Genetic strategy III |
IL130162A (en) * | 1996-12-12 | 2008-03-20 | Yissum Res Dev Co | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US6475998B1 (en) * | 1997-03-06 | 2002-11-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for the treatment of injury to the central nervous system |
US6869795B1 (en) | 1999-10-07 | 2005-03-22 | Avi Biopharma, Inc. | Antisense compositions and cancer-treatment methods |
JP2003511393A (ja) * | 1999-10-07 | 2003-03-25 | エイブイアイ バイオファーマ, インコーポレイテッド | アンチセンス組成物および癌処置法 |
IL132972A0 (en) * | 1999-11-16 | 2001-03-19 | Yissum Res Dev Co | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders |
US6770799B2 (en) * | 2000-03-17 | 2004-08-03 | Thompson Boyce Plant Res | Expression of recombinant human acetylcholinesterase in transgenic plants |
IL143379A (en) * | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
US7049121B2 (en) * | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
WO2003054182A2 (en) * | 2001-12-21 | 2003-07-03 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
US20060253913A1 (en) * | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
US7480382B2 (en) * | 2003-09-30 | 2009-01-20 | Microsoft Corporation | Image file container |
IL158600A (en) * | 2003-10-26 | 2015-07-30 | Hermona Soreq | Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent |
US7968762B2 (en) * | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
CN101437933B (zh) * | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | 作为药物靶标的天然反义和非编码的rna转录物 |
WO2008019036A2 (en) * | 2006-08-04 | 2008-02-14 | Pharmathene Inc. | Long half-life recombinant butyrylcholinesterase |
RU2604489C2 (ru) * | 2008-10-03 | 2016-12-10 | КьюРНА,Инк.,US | Лечение заболеваний, связанных с аполипопротеином-а1, путем ингибирования природного антисмыслового транскрипта аполипопротеина-а1 |
EP2727996A1 (en) | 2008-11-06 | 2014-05-07 | The Johns-Hopkins University | Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors |
EP2373338B1 (en) | 2008-12-03 | 2017-02-15 | The Johns Hopkins University | Annexina2 as immunological target |
US8927511B2 (en) * | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
MX2011005918A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen. |
ES2629630T3 (es) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO |
CA2752237C (en) | 2009-02-12 | 2020-03-24 | Opko Curna, Llc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
CA2755409C (en) | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
CA2755404C (en) | 2009-03-17 | 2020-03-24 | Joseph Collard | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
CA2761142C (en) | 2009-05-06 | 2021-06-08 | Opko Curna, Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
CN103223177B (zh) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
US9012139B2 (en) | 2009-05-08 | 2015-04-21 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family |
CN102575251B (zh) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病 |
US8895527B2 (en) | 2009-05-22 | 2014-11-25 | Curna, Inc. | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
CA2764683A1 (en) | 2009-05-28 | 2010-12-02 | Joseph Collard | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
JP6128846B2 (ja) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療 |
ES2620960T3 (es) | 2009-06-16 | 2017-06-30 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen de colágeno mediante la inhibición de un transcrito antisentido natural a un gen de colágeno |
JP6073133B2 (ja) | 2009-06-24 | 2017-02-01 | クルナ・インコーポレーテッド | 腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療 |
WO2010151674A2 (en) | 2009-06-26 | 2010-12-29 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
KR101801407B1 (ko) | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료 |
KR101802536B1 (ko) | 2009-08-05 | 2017-11-28 | 큐알엔에이, 인크. | 인슐린 유전자 (ins)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ins) 관련된 질환의 치료 |
WO2011019815A2 (en) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
JP5943836B2 (ja) | 2009-08-21 | 2016-07-05 | カッパーアールエヌエー,インコーポレイテッド | ‘hsp70相互作用タンパク質c末端’(chip)に対する天然アンチセンス転写産物の阻害によるchip関連疾患の治療 |
JP5964232B2 (ja) | 2009-08-25 | 2016-08-03 | カッパーアールエヌエー,インコーポレイテッド | ‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療 |
JP6175236B2 (ja) | 2009-09-25 | 2017-08-09 | カッパーアールエヌエー,インコーポレイテッド | フィラグリン(flg)の発現および活性の調整によるflg関連疾患の処置 |
DK2513310T3 (en) | 2009-12-16 | 2018-02-05 | Curna Inc | TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1 |
WO2011084145A2 (en) | 2009-12-21 | 2011-07-14 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
EP2515947B1 (en) | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
JP5993744B2 (ja) | 2009-12-29 | 2016-09-14 | カッパーアールエヌエー,インコーポレイテッド | 核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療 |
EP2519634B1 (en) | 2009-12-29 | 2016-06-01 | CuRNA, Inc. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
EP2521784B1 (en) | 2010-01-04 | 2017-12-06 | CuRNA, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
ES2664866T3 (es) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
DK2529015T3 (en) | 2010-01-25 | 2018-02-26 | Curna Inc | TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1 |
CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病 |
KR20130101442A (ko) | 2010-05-03 | 2013-09-13 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
JP5973996B2 (ja) | 2010-05-26 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Atoh1に対する天然アンチセンス転写物の阻害による無調ホモログ1(atoh1)関連疾患の治療 |
RU2620978C2 (ru) | 2010-05-26 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra |
RU2016118528A (ru) | 2010-06-23 | 2018-10-31 | Курна, Инк. | Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna |
RU2611190C2 (ru) | 2010-07-14 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg |
US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
US9222088B2 (en) | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
KR102010598B1 (ko) | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료 |
CN103620036B (zh) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病 |
EA029151B1 (ru) | 2011-09-06 | 2018-02-28 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ |
EP2898072A1 (en) | 2012-09-24 | 2015-07-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Restoration of the cftr function by splicing modulation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0402402B1 (en) * | 1988-02-26 | 1995-12-27 | Worcester Foundation For Biomedical Research, Inc. | Inhibition of htlv-iii by exogenous oligonucleotides |
US5225326A (en) * | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
CA2089563C (en) * | 1990-08-14 | 2004-04-06 | Clarence Frank Bennett | Oligonucleotide modulation of cell adhesion |
-
1992
- 1992-04-15 IL IL10160092A patent/IL101600A/xx not_active IP Right Cessation
-
1993
- 1993-04-15 WO PCT/EP1993/000911 patent/WO1993021202A1/en active IP Right Grant
- 1993-04-15 DE DE69308833T patent/DE69308833T2/de not_active Expired - Lifetime
- 1993-04-15 AU AU40399/93A patent/AU665087B2/en not_active Ceased
- 1993-04-15 US US08/318,826 patent/US5891725A/en not_active Expired - Fee Related
- 1993-04-15 AT AT93911467T patent/ATE150029T1/de not_active IP Right Cessation
- 1993-04-15 JP JP5517984A patent/JPH08504083A/ja active Pending
- 1993-04-15 CA CA002118235A patent/CA2118235C/en not_active Expired - Fee Related
- 1993-04-15 EP EP93911467A patent/EP0636137B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE150029T1 (de) | 1997-03-15 |
EP0636137A1 (en) | 1995-02-01 |
AU665087B2 (en) | 1995-12-14 |
AU4039993A (en) | 1993-11-18 |
US5891725A (en) | 1999-04-06 |
DE69308833D1 (de) | 1997-04-17 |
CA2118235A1 (en) | 1993-10-28 |
JPH08504083A (ja) | 1996-05-07 |
DE69308833T2 (de) | 1997-06-19 |
CA2118235C (en) | 2008-07-15 |
WO1993021202A1 (en) | 1993-10-28 |
IL101600A0 (en) | 1992-12-30 |
EP0636137B1 (en) | 1997-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL101600A (en) | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them | |
CA2229811A1 (en) | Inverted chimeric and hybrid oligonucleotides | |
CA2046916A1 (en) | Methods and compositions for treatment of cancer using oligonucleotides | |
EP0939621A4 (en) | INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODE OXYNUCLEOTIDE | |
AU7621600A (en) | Human rnase h and oligonucleotide compositions thereof | |
AU7572096A (en) | Chimeric oligomers having an rna-cleavage activity | |
MX9700270A (es) | Composicion que contiene acidos nucleicos, preparacion y utilizacion. | |
ZA935915B (en) | Modified fungal cells and method for producing recombinant products | |
CA2205075C (en) | Reagent and method for inhibition of n-ras expression | |
WO1998011211A3 (en) | Method for using oligonucleotides having modified cpg dinucleosides | |
WO1994025588A2 (en) | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) | |
CA2398432A1 (en) | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides | |
AU5959396A (en) | Antisense oligonucleotide modulation of raf gene expression | |
Baserga | Controlling IGF-receptor function: a possible strategy for tumor therapy | |
CA2259123A1 (en) | Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth | |
IL115473A (en) | Pharmaceutical compositions and compounds for inhibition of stem cell proliferation, use of such compounds in the manufacture of medicaments for this purpose, and in vitro methods for treating bone marrow and for preparing hematopoietic cells for therapy | |
EP1123414A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4 | |
AU3295700A (en) | Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same | |
WO1996002556A2 (en) | Oligonucleotides with anti-mdr-1 gene activity | |
Birek et al. | Secretion of a bone resorbing factor by epithelial cells cultured from porcine rests of Malassez | |
NZ504445A (en) | Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive | |
AU5005093A (en) | Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer | |
EP0695354A1 (en) | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-$g(b) (TGF-$g(b)) | |
IL146565A0 (en) | A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5 | |
AU784358B2 (en) | Antisense compositions and cancer-treatment methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |